胺碘酮和普罗帕酮治疗冠心病并室性心律失常的疗效比较

比较胺碘酮和普罗帕酮治疗冠心病心肌缺血患者室性心律失常的疗效。6 9例冠心病心肌缺血合并室性心律失常患者 ,均接受冠心病正规治疗 ,其中 35例同时口服胺碘酮片 (胺碘酮组 ) ,34例口服普罗帕酮片 (普罗帕酮组 ) ,疗程 4周。疗程开始及结束时均行 2 4h动态心电图及 12导联心电图检查。结果 :两组患者用药后 2 4h室性早搏 ,短阵室性心动过速的发作次数均明显减少 (胺碘酮组用药后与用药前比较分别为 2 70 5± 14 77个vs 6 834± 45 2 8个 ,7.4 2± 3.30次vs 1.2 9± 0 .93次 ;普罗帕酮组则分别为 6 712± 3385个vs 396 2± 1983个 ,8.0 5± 3.37次vs4 .2 2± 2 .5 9次 ,P均 <0 .0 1)。胺碘酮组的疗效高于普罗帕酮组 (P <0 .0 1)。两组未见严重副作用。结论 :胺碘酮对冠心病伴室性心律失常的疗效优于普罗帕酮。

Therapeutic Effect of Amiodarone Compared With Propafenone on Ventricular Arrhythmias in Coronary Heart Diseases

To investigate the effect and safety of amiodarone (Cordarone) and propafenone ventricular arrhythmias(VAs) in patients with coronary heart diseases(CHD),69 patients of CHD with VA accepted the standad therapy of CHD. Among them,35 patients were tre ated with amiodarone(amiodarone group) and 34 patients were treated with propafenone (prop afenone group). Results:In both groups, the occurrence of ventricular arrhythmias were reduced markedly.Premature ventricular beats and parsymal ventricular tachycardia s before and after treatment in amiodarone group were 6 834±4 528 beats/24 h an d 2 705±1 477 beats/24 h,8.05±3.37 times/24 h and 4.22±2.59 times/24 h,respe ctively.And in propafenone group wer 6 712±3 385 beats/24 h vs 3 926±1 983 bea ts/24 h and 8.05±3.37 times/24 h vs 4.22±2.59 times/24 h,respectively. A ll P<0.01.There was a better effect amiodarone group than propafenone group( P<0.01). No heart function deterioration occurred in both group. Conclusion:There is obvious therapeutic ef ficacy of amiodarone on CHD with VAs and better than propafenone.